Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical
company developing cancer stem cell-related therapeutics, today announced the
appointment of ProActive Capital Group as its new Capital Markets Advisory and
Digital Media Strategies firm.


"We are very pleased to have retained the services of ProActive Capital Group,"
stated Stem Cell Therapeutics' Chief Executive Officer, Dr. Niclas Stiernholm.
"They are an extremely focused firm with an excellent reputation in the industry
and we are excited to adopt an effective capital markets and digital media
program. With upcoming key milestones quickly approaching, we feel that now is
the opportune time to embark on a significant new and expanded program so that
we can achieve a fair valuation that clearly reflects the intrinsic value of our
scientific programs."


"We are delighted to have been selected by Stem Cell Therapeutics, a leading
company in the cancer stem cell space," stated Jeff Ramson, Founder and CEO of
ProActive Capital Group. "We look forward to developing and implementing a
quality capital markets and digital media strategy to increase SCT's visibility
among the investment community. We strongly believe that the company has
significant prospects as it executes its growth strategy."


The Company also announced that the board of directors has approved the adoption
of a Deferred Share Unit plan (the "DSU Plan") subject t o the approval of the
shareholders of the Company and acceptance by the TSX Venture Exchange. The DSU
Plan provides an alternative non-cash form of compensation to satisfy annual and
special bonuses payable to directors and executive officers, and to satisfy fees
that may be payable to directors for acting as directors of the Company. This
form of compensation promotes a greater alignment of interests amongst directors
and executive officers and the Company's shareholders since DSU Units are
ultimately exchanged for common shares of the Company. The maximum number of
common shares that may be reserved for issuance under the DSU Plan is set at
2,000,000 common shares.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT), a Toronto-based biopharmaceutical company,
is Canada's only public company dedicated to advancing cancer stem cell
discoveries into novel and innovative cancer therapies. Building on over half a
century of leading and groundbreaking Canadian stem cell research, the company
is supported by established links to a group of Toronto academic research
institutes and cancer treatment centers, representing one of the world's most
acclaimed oncology research hubs. SCT's clinical stage programs include the
recently in-licensed tigecycline program, which is currently being evaluated in
a multi-centre Phase I study in patients with Acute Myeloid Leukemia (AML), as
well as TTI-1612, a non-stem cell asset that recently completed a 28-patient
Phase I trial in interstitial cystitis ("IC") patients. The Company also has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. For more information,
visit: www.stemcellthera.com


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


ProActive Capital
Jeff Ramson
Investor Contact
(646) 863-6341
jramson@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.